Alternative therapies in patients with non-muscle invasive bladder cancer.

Sanli O., Lotan Y.

Turkish journal of urology, cilt.43, sa.4, ss.414-424, 2017 (Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 43 Sayı: 4
  • Basım Tarihi: 2017
  • Doi Numarası: 10.5152/tud.2017.64624
  • Dergi Adı: Turkish journal of urology
  • Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.414-424
  • Anahtar Kelimeler: BCG, bladder cancer, instillation, survival, BACILLUS-CALMETTE-GUERIN, TRANSITIONAL-CELL CARCINOMA, RANDOMIZED CONTROLLED-TRIAL, ALBUMIN-BOUND PACLITAXEL, PHASE-III TRIAL, MITOMYCIN-C, UROTHELIAL CARCINOMA, INTRAVESICAL CHEMOTHERAPY, ONCOLYTIC ADENOVIRUS, MARKER LESION
  • İstanbul Üniversitesi Adresli: Evet

Özet

Bladder cancer (BC) is one of the leading causes of cancer-related deaths worldwide. Despite, the majority of the cases were diagnosed as non-muscle invasive bladder cancer (NMIBC) with favorable prognosis, it has tendency to recur or progress to a higher grade or stage. The first line treatment of patients with NMIBC is transurethral resection with adjuvant therapies primarily intravesical Bacillus Calmette-Guerin (BCG) immunotherapy. However, in a portion of patients whose BCG treatment failed, alternative treatments may be required. Furthermore, intravesical BCG may be contraindicated in or untolerated by a group of patients. For these patients, some treatment options are readily available and a variety of them are currently under clinical investigation. In this review, these alternative therapies have been summarized.